AIDS Alert Archives – December 1, 2011
December 1, 2011
View Archives Issues
-
HIV/AIDS epidemic at 30 years: Promised land or wasteland?
Thirty years after the world first became aware of a strange syndrome that caused young men to acquire rare diseases like Pneumocystis carinii pneumonia (PCP) and Kaposi's Sarcoma, nations across the globe continue to battle against the HIV/AIDS epidemic. -
HIV prevention goal still elusive
Researchers who have closely studied the United States' national HIV/AIDS prevention strategy as it has developed over the past three decades have concluded that it has been underfunded, and it's very difficult to implement. -
Rethinking metrics used for goals
One obstacle to the success of the U.S. national HIV/AIDS strategy involves the accuracy of metrics used for monitoring HIV care, including late diagnoses and linkage to sustained care, a new study notes. -
Study looks at state disparities in HIV
HIV/AIDS mortality data highlight disparities between states, suggesting differences in HIV treatment and care, a new study shows.1 -
AMA: Amend HIV transplant law
The American Medical Association recently voted to support amending a federal law that bars clinical research of HIV-infected organ donation, as a potentially lifesaving measure for people living with HIV infection. -
What's new in HIV treatment?
A revision to the Jan. 10, 2011, Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents was published on Oct. 14, 2011. -
Abstract & Commentary: HIV-1 Protein linked to insulin resistance
3T3L1 pre-adipocytes in cell culture were treated overnight with myristoylated or non-myristoylated recombinant Nef. Glucose uptake was measured with and without insulin stimulation. -
FDA Notifications
Updates to the darunavir (Prezista®) package insert, specifically sections: 6 Adverse Reactions, 12.4 Microbiology, 14 Clinical Studies and were approved on Oct. 19, 2011, to include results from the 192-week safety, resistance and efficacy data from study TMC114-C211, "A randomized, controlled, open-label Phase 3 trial comparing darunavir/ritonavir 800/100 mg once daily versus lopinavir/ritonavir 800/200 mg per day (given as a twice daily or as a once daily regimen) in antiretroviral treatment-naïve HIV-1-infected adult subjects."